Matinas BioPharma says warrant exercise brings in about $2.6 million cash proceeds

Matinas BioPharma Holdings, Inc.

Matinas BioPharma Holdings, Inc.

MTNB

0.00
  • Matinas BioPharma disclosed a warrant inducement that led to the immediate cash exercise of existing warrants for 7,486,605 common shares at USD 0.35.
  • Gross proceeds from the exercises were about USD 2.6 million.
  • In exchange, it will issue new unregistered warrants to buy up to 7,486,605 common shares at USD 0.35, subject to stockholder approval.
  • Separately, it issued warrants to buy up to 1,642,856 common shares alongside a USD 575,000 Series D convertible preferred stock private placement.
  • The shares underlying the exercised existing warrants were registered for resale under an effective Form S-3 registration statement.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Matinas BioPharma Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607130800PRIMZONEFULLFEED9760825) on July 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.